{"classes":[{"categories":[{"measurements":[{"comment":"Median duration of response for group 1 was not attained.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median duration of response for group 2 was not attained.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Duration of response was calculated from the documentation (date) of first response (CR, nCR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"OG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"OG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved a partial response(PR) or better were evaluable for this analysis.","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 12 cycles)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}